p53 mutations as fingerprints of environmental carcinogens
Pure and Applied Chemistry
995 - 999
MetadataShow full item record
Please cite this item using this persistent URLhttp://hdl.handle.net/11693/27635
Mutations of the p53 tumor suppressor gene occur in a great majority of human cancers. The protein product of p53 gene is involved in DNA damage response. Consequently, p53 gene may be a preferred target for environmental carcinogens, which also act as DNA-damaging agents. This is probably why p53 mutations are frequent in cancers linked to environmental carcinogens. Moreover, these carcinogens leave molecular fingerprints on the p53 gene. Thus, the study of p53 mutation spectra has been a useful approach to implicate suspected carcinogens to different human cancers. This review provides further insight into the significance of p53 mutation spectra in ten common human malignancies (skin, liver, lung, bladder, breast, head and neck, esophagus, stomach and colorectal cancers, and hematological malignancies), in relation with environmental carcinogens.
Showing items related by title, author, creator and subject.
Adjuvant Autologous Melanoma Vaccine for Macroscopic Stage III Disease: Survival, Biomarkers, and Improved Response to CTLA-4 Blockade Lotem M.; Merims S.; Frank S.; Hamburger T.; Nissan A.; Kadouri L.; Cohen J.; Straussman R.; Eisenberg G.; Frankenburg S.; Carmon E.; Alaiyan B.; Shneibaum S.; Ayyildiz Z.O.; Isbilen M.; Senses K.M.; Ron I.; Steinberg H.; Smith Y.; Shiloni E.; Gure A.O.; Peretz T. (Hindawi Limited, 2016)Background. There is not yet an agreed adjuvant treatment for melanoma patients with American Joint Committee on Cancer stages III B and C. We report administration of an autologous melanoma vaccine to prevent disease ...
Gunduz-Demir, C. (2007)We report a novel computational method based on graph evolution process to model the malignancy of brain cancer called glioma. In this work, we analyze the phases that a graph passes through during its evolution and ...
TRIB2 confers resistance to anti-cancer therapy by activating the serine/threonine protein kinase AKT Hill R.; Madureira P.A.; Ferreira B.; Baptista I.; Machado S.; Colaço L.; Dos Santos M.; Liu N.; Dopazo A.; Ugurel S.; Adrienn A.; Kiss-Toth E.; Isbilen M.; Gure A.O.; Link W. (Nature Publishing Group, 2017)Intrinsic and acquired resistance to chemotherapy is the fundamental reason for treatment failure for many cancer patients. The identification of molecular mechanisms involved in drug resistance or sensitization is imperative. ...